U.S. markets closed

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
0.4298+0.0197 (+4.80%)
Al cierre: 04:00PM EDT
0.4387 +0.01 (+2.07%)
Fuera de horario: 07:59PM EDT

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
858 550 0780
https://www.traconpharma.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo17

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Charles P. Theuer M.D., Ph.D.Chairman, CEO & President646.6kN/D1964
Mr. Scott B. Brown CPA, M.S.Chief Financial Officer403.1kN/D1981
Dr. James L. FreddoChief Medical OfficerN/DN/D1955
Mr. Ya HuangExecutive Director of Statistical ProgrammingN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de TRACON Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.